Login to Your Account



TopoTarget HDAC Bull's Eye: 'Spectrum' of Benefit Ahead?

By Randy Osborne
BioWorld International Contributing Writer

Wednesday, September 26, 2012
TopoTarget A/S' positive results from the BELIEF pivotal trial with belinostat could mean upside for U.S. partner Spectrum Pharmaceuticals Inc., if the histone deacetylase (HDAC) inhibitor is approved for peripheral T-cell lymphoma, but the latest outcome with belinostat is "not really a game changer for this drug," said Decision Resources analyst Lisa Murch.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription